In our new monthly news roundups, we will be sharing our news, updates, and highlights from the past few weeks.
To discuss any of our updates, please contact Dr Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea BioLabs, who will be happy to help.
June 2023 news roundup
Agreement with Oncobone
Inaphaea has entered into an agreement with virtual CRO services company, OncoBone Limited, to allow the use by clients of OncoBone services provided by Inaphaea BioLabs.
OncoBone designs and commissions pre-clinical work on behalf of clients and, as such, engages external CRO’s to execute on the experimental designs that OncoBone has developed. Inaphaea is now confirmed as an OncoBone supplier of cell-based assays.
For more information, read the story here.
Imagen Therapeutics asset acquisition
Our parent company ValiRx PLC announced the acquisition of the scientific assets of Imagen Therapeutics Limited from its appointed liquidators.
UK pharmaceutical services company Imagen offered personalised cancer treatment through the collection and use of well-characterised, patient-derived cells.
The asset acquisition will see Imagen’s biobank and relevant equipment transferred and integrated into Inaphaea BioLabs within the next few months.
Meet Lead Scientist, Melissa Barr
In the second instalment of our ‘meet the team’ series for Inaphaea BioLabs, we sat down with our Lead Scientist, Melissa Barr, to find out more about her background, experience and plans and ambitions for the new laboratory.
Read the blog here.
Inaphaea listed on Scientist.com
We are pleased that Inaphaea BioLabs’ cell-based assay services are now listed on Scientist.com – a database of CROs that can be used by biotechnology and pharmaceutical companies to search for scientific capabilities.
Busy events calendar
2023 is proving to be a busy year for Inaphaea so far, and our events schedule is no different, with the team attending events up and down the country to meet potential project partners and network with fellow life sciences professionals.
This month, Andrew attended the Innovation Summit at Discovery Park on 22 June, and BioNow’s ‘Biotech & Beers’ on 27 June in Newcastle. In July, he is looking forward to attending One Nucleus’ On-Helix event (6 July), as well as the OBN Summer Drinks on 19 July in London.
If you would like to connect with us at these events, please do get in touch here.